MAPK1 and rhabdomyosarcoma: In rhabdomyosarcoma, for example, through the RAF–MEK–ERK MAPK pathway, oncogenic RAS inhibits myogenic differentiation by reducing MYOG expression, which is mediated by ERK2-dependent promoter-proximal stalling of RNA pol II at the MYOG locus.